03-05-2023 : 769 Pharmacists work as Medical Representative, of which 39 work as Senior Medical Representative * 02-06-2020 : 216 non Pharmacists work as Medical Representative, and 54 work as Senior Medical Representative * 05-06-2023 : In Lebanon, 88 generic medicinal products are more expensive than their Originators * 31-12-2019 : A medicinal product refused in Europe is marketed in Lebanon * 05-06-2023 : At least 332 medicinal products are available on the Lebanese market and are not available in the country of origin * 05-06-2023 : The price of the most expensive medicine available in Lebanon is 30434557 LL * 05-06-2023 : At least 1309 medicinal products are more expensive in Lebanon than in the countries of origin * 01-01-2019 : Daktavira, a generic of Daklinza, is registered in Lebanon but has no public price * 31-12-2019 : 352 medicinal products have been declared as non-marketed or withdrawn * 09-11-2021 : 64.72% of lebanese pharmacists are female * 31-12-2019 : 486 medicines were submitted to the Ministry of Health for a marketing authorization, and 514 medicines were registered to date * 15-06-2018 : The Minister of Public Health, has decided to suspend the commercialization of AB Slim (Ab Care Medical Herbs), which contains sibutramine, sildenafil and phenolphthalein * 01-06-2020 : Some Non-Marketed medicines are still imported * 01-06-2020 : Ixempra, a medicinal product withdrawn in Europe is imported to lebanon * 01-06-2020 : A vaccine made in India, removed from WHO list of prequalified vaccines, is submitted for registration in Lebanon * 01-06-2020 : Lebanon has 14 CROs, and is ranked as one of the largest countries in the world in clinical studies. According to the WHO, 817 clinical studies are currently conducted in Lebanon. * 05-01-2021 : * 01-10-2023 : Adakveo is now withdrawn from use in the European Union due to lack of therapeutic efficacy *
Tresiba Pen* : | |
Type | Medicine Non Marketed |
Originator | Biotech (Tresiba Stylo) |
Agent | Mersaco |
Distributor | Mersaco |
Laboratory | Novo Nordisk |
Responsible Party | Novo Nordisk AS |
Origin | Denmark |
Manufacturer | Novo Nordisk AS |
Origin | Denmark |
ATC | A10AE06 |
Tresiba Pen* :
Tresiba Pen* :
Tresiba Pen* :
Tresiba Pen* :
Tresiba Pen* :
Hazard Level |
---|
◼ Major |
◼ Moderate |
◼ Minor |
◼ Safe |
Tresiba Pen* :
Frequency | Percentage |
---|---|
Very Common | ≥ 1/10 |
Common | ≥ 1/100 - < 1/10 |
Uncommon | ≥ 1/1,000 - < 1/100 |
Rare | ≥ 1/10,000 - < 1/1,000 |
Very Rare | < 1/10,000 |
Unknown | Cannot be Estimated |
Effect | Frequency |
---|---|
Diarrhoea (Diarrhea) | Rare |
Fatigue | Rare |
Hypersensitivity | Rare |
Hypoglycaemia | Very Common |
Injection site discolouration | Common |
Injection site erythema | Common |
Injection site haematoma | Common |
Injection site haemorrhage | Common |
Injection site mass | Common |
Injection site nodule | Common |
Injection site pain | Common |
Injection site pruritus | Common |
Injection site reaction | Common |
Injection site swelling | Common |
Injection site warmth | Common |
Lip swelling | Rare |
Lipoatrophy | Uncommon |
Lipodystrophy acquired | Uncommon |
Lipohypertrophy | Uncommon |
Nausea | Rare |
Oedema peripheral | Uncommon |
Pruritus | Rare |
Swollen tongue | Rare |
Urticaria | Rare |
NB : Products With Same Indication |
Different Units By MoH Code
Tresiba Pen* MoH 7241 :
Form | Solution for injection |
Packaging | Pen |
Package Size | 3x3ml |
Strength | 100IU/ml |
Storage Condition | 2-8°C Do not freeze |
NSSF | ✘ |
Quarantine | ✘ |
Reg. Number | 187330/13 |
Submission date | 01/01/2013 |
Registration Year | 2013 |
Archived Date | 2016 |
Price Comparison
You have to register to view this info
Drop File